This HTML5 document contains 77 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n25http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/chebi/
n20http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/wikipedia/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/pharmgkb/
n17http://bio2rdf.org/drugbank:
n27http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n19http://www.rxlist.com/cgi/generic/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/pubchem-substance/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/drugbank/
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01406/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01406
rdf:type
n3:Drug
n3:description
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. [PubChem]
n3:dosage
n8:271B46F2-363D-11E5-9242-09173F13E4C5 n8:271B46F3-363D-11E5-9242-09173F13E4C5 n8:271B46F4-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Dmowski WP: Danazol. A synthetic steroid with diverse biologic effects. J Reprod Med. 1990 Jan;35(1 Suppl):69-74; discussion 74-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2404115 # Donaldson VH: Danazol. Am J Med. 1989 Sep;87(3N):49N-55N. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2486535 # Jenkin G: Review: The mechanism of action of danazol, a novel steroid derivative. Aust N Z J Obstet Gynaecol. 1980 May;20(2):113-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6998453
n3:group
approved
n3:halfLife
Approximately 24 hours.
n3:indication
For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
owl:sameAs
n17:DB01406 n18:DB01406
dcterms:title
Danazol
adms:identifier
n10:Danazol n13:PA164749056 n21:D00289 n22:0024-0305-60 n23:DB01406 n24:4315 n25:26436 n26:46506475 n27:28417
n3:mechanismOfAction
As a gonadotropin inhibitor, danazol suppresses the pituitary-ovarian axis possibly by inhibiting the output of pituitary gonadotropins. Danazol also depresses the preovulatory surge in output of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thereby reducing ovarian estrogen production. Danazol may also directly inhibits ovarian steroidogenesis; bind to androgen, progesterone, and glucocorticoid receptors; bind to sex-hormone-binding globulin and corticosteroid-binding globulin; and increases the metabolic clearance rate of progesterone. Another mechanism of action by which danazol may use to facilitate regression of endometriosis is by decreasing IgG, IgM, and IgA concentrations, as well as phospholipid and IgG isotope autoantibodies. In the treatment of endometriosis, as a consequence of suppression of ovarian function, danazol causes both normal and ectopic endometrial tissues to become inactive and atrophic. This leads to anovulation and associated amenorrhea. In fibrocystic breast disease, the exact mechanism of action of danazol is unknown, but may be related to suppressed estrogenic stimulation as a result of decreased ovarian production of estrogen. A direct effect on steroid receptor sites in breast tissue is also possible. This leads to a disappearance of nodularity, relief of pain and tenderness, and possibly changes in the menstrual pattern. In terms of hereditary angioedema, danazol corrects the underlying biochemical deficiency by increasing serum concentrations of the deficient C1 esterase inhibitor, resulting in increased serum concentrations of the C4 component of the complement system. (Source: PharmGKB)
n3:packager
n4:271B46E4-363D-11E5-9242-09173F13E4C5 n4:271B46E2-363D-11E5-9242-09173F13E4C5 n4:271B46E7-363D-11E5-9242-09173F13E4C5 n4:271B46E8-363D-11E5-9242-09173F13E4C5 n4:271B46E5-363D-11E5-9242-09173F13E4C5 n4:271B46E6-363D-11E5-9242-09173F13E4C5 n4:271B46E9-363D-11E5-9242-09173F13E4C5 n4:271B46E3-363D-11E5-9242-09173F13E4C5
n3:synonym
Cyclomen Danazolum Danocrine
n6:hasAHFSCode
n20:68-08-00
n3:foodInteraction
Take without regard to meals.
n3:synthesisReference
Clinton, R. and Hanson, A.; US. Patent 3,135,743; June 2, 1964; assigned to Sterling Drug.
foaf:page
n12:danazol.html n19:danazol.htm
n3:IUPAC-Name
n5:271B46F9-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B46FF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B46FE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B46FB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B46FC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B46FD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B46F7-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B46F8-363D-11E5-9242-09173F13E4C5 n5:271B4710-363D-11E5-9242-09173F13E4C5 n5:271B46F5-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B46F6-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:G03XA01
n3:H-Bond-Acceptor-Count
n5:271B4705-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4706-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4700-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4701-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4703-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4702-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4704-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
17230-88-5
n3:containedIn
n15:271B46EE-363D-11E5-9242-09173F13E4C5 n15:271B46EC-363D-11E5-9242-09173F13E4C5 n15:271B46ED-363D-11E5-9242-09173F13E4C5 n15:271B46EA-363D-11E5-9242-09173F13E4C5 n15:271B46EB-363D-11E5-9242-09173F13E4C5 n15:271B46F1-363D-11E5-9242-09173F13E4C5 n15:271B46EF-363D-11E5-9242-09173F13E4C5 n15:271B46F0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B470B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B470D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B470E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B470F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B470A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4709-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B470C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B46FA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4707-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4708-363D-11E5-9242-09173F13E4C5